



SCIENTIFIC PUBLICATION LIST

Sep 2019



www.resonancehealth.com

info@resonancehealth.com

FERRISCAN SCIENTIFIC PUBLICATION LIST

KEY PAPERS

St. Pierre TG et al. Non-invasive measurement and imaging of liver iron concentrations using proton magnetic resonance. *Blood* 2005; 105 (2):855-861. [\[Link to abstract\]](#)

Pavitt H et al. The effect of reducing repetition time TR on the measurement of liver R2 for the purpose of measuring liver iron concentration. *Magn Reson Med.* 2011; 65(5):1346-51. [\[Link to abstract\]](#)

Brown GC et al. Spin-density-projection-assisted R2 magnetic resonance imaging of the liver in the management of body iron stores in patients receiving multiple red blood cell transfusions: an audit and retrospective study in South Australia. *Int Med J.* 2012; 30 May. DOI:10.1111/j.1445-5994.2012.02845.x. [\[Link to abstract\]](#)

Taher AT et al. Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1 year results from a prospective, randomized, double-blind, placebo-controlled study. *American Society of Haematology.* 2012; 120:970-77. [\[Link to abstract\]](#)

St Pierre TG et al. Multicenter validation of spin-density projection-assisted R2-MRI for the noninvasive measurement of liver iron concentration. *Magn Reson Med.* (2013), doi: 10.1002/mrm.24 [\[Link to paper\]](#)

Taher, AT et al. Deferasirox demonstrates a dose-dependent reduction in liver iron concentration and consistent efficacy across subgroups of non-transfusion-dependent thalassemia patients. *American Journal of Hematology,* 2013. 88(6): p. 503-506. doi:10.1002/ajh.23445. [\[Link to abstract\]](#)

GUIDELINES

UK Thalassaemia Society. Standards for the clinical care of children and adults with Thalassaemia in the UK. 2016. [\[Link to guideline\]](#)

Tubman, VN, et al. Guidelines for the Standard Monitoring of Patients With Thalassemia: Report of the Thalassemia Longitudinal Cohort. *Journal of pediatric hematology/oncology,* 2015. 37(3): p. e162-e169. [\[Link to guideline\]](#)

Thalassaemia International Federation. Guidelines for the Management of Transfusion Dependent Thalassaemia (TDT) 3rd Edition 2014. Porter, J et al. in *Iron Overload and Chelation.* [\[Link to guideline\]](#)

Royal College of Obstetricians and Gynaecologists (UK). Management of Beta Thalassaemia in Pregnancy Green-Top Guideline no. 66. 2014. [\[Link to guideline\]](#)

ASH Education Program Book, 2013. Consequences and management of iron overload in sickle cell disease. Porter, J and M Garbowski. 2013(1): p. 447-456. [\[Link to guideline\]](#)

The Fred Hutchinson Cancer Research Center / Seattle Cancer Care Alliance -Long-term follow-up after hematopoietic stem cell transplant general guidelines for referring physicians (April 2013) [\[Link to guideline\]](#)

University Health Network - Toronto General Hospital. Guidelines for the care of patients in UHN Red Blood Cell Disorders Program. 2012. [\[Link to guideline\]](#)

Northern California Comprehensive Thalassemia Network and Children's Hospital, Oakland. 2012 Thalassemia Standards of Care Guidelines. [\[Link to guideline\]](#)

Diamond Blackfan Anemia Foundation, Inc. Diamond Blackfan Anemia Chelation Therapy Fact Sheet. [\[Link to factsheet\]](#)

Ho PJ et al. Australian guidelines for the assessment of iron overload and iron chelation in transfusion-dependent thalassaemia major, sickle cell disease and other congenital anaemias. *Internal Medicine Journal.* 2011; 41(7): 516-24. [\[Link to abstract\]](#)

Santini V et al. Clinical Management of myelodysplastic syndromes: updated of SIE, SIES, GITMO practice guidelines. *Leukemia Research.* 2010; 34:1576-88. [\[Link to abstract\]](#)

Cooley's Anemia Foundation. 2012 Position Statement on MRI-Based Hepatic Iron Assessment Methods. [\[Link to article\]](#)

Angelucci E et al. Italian Society of Hematology practice guidelines for the management of iron overload in thalassaemia major and related disorders. *Haematologica* 2008;93(5):741-752. [\[Link to full article\]](#)

Wells D et al. Iron overload in myelodysplastic syndromes: a Canadian consensus guideline. *Leukemia Research.* 2008; 32(9):1338-53. [\[Link to abstract\]](#)

Thalassaemia International Federation. Guidelines for the clinical management of Thalassaemia (2nd revised edition). 2008. [\[Link to guideline\]](#)

UK Sickle Cell Society. Standards for the clinical care of adults with sickle cell disease in the UK (1st edition). 2008. [\[Link to guideline\]](#)

International Association of Sickle Cell Nurses and Physician Assistants. Nursing Practice Guideline: Care of the patients with sickle cell disease and iron overload. 2008. http://www.iascnapa.org/guidelines/Guidelines_IronOverlo ad.pdf

US Department of Health and Human Services. Evidence-based Management of Sickle Cell Disease, Expert Panel Review, 2014. [\[Link to guideline\]](#)

FERRISCAN SCIENTIFIC PUBLICATION LIST

Association of the Scientific Medical Societies in Germany. Guideline for diagnosis and treatment of secondary iron overload in patients with congenital anemias, 2015. [[Link to guideline](#)]

Rovira M., Suárez-Lledó M. (2019) Short- and Long-Term Controls After HSCT. In: Carreras E., Dufour C., Mohty M., Kröger N. (eds) The EBMT Handbook. Springer, Cham [[Link to abstract](#)]

ORIGINAL ARTICLES

Huang Y, et al. Imbalance of erythropoiesis and iron metabolism in patients with thalassemia. *International journal of medical sciences*. 2019;16(2):302. [[Link to article](#)]

Aishwariya P, et al. Spontaneous iliopsoas hematoma in a transfusion dependent β -thalassemia patient with hypersplenism: a case report. *Acta bio-medica: Atenei Parmensis*. 2019;90(1):107. [[Link to article](#)]

Britton L, et al. Hepatic iron concentration correlates with insulin sensitivity in nonalcoholic fatty liver disease. *Hepatology communications*. 2018 Jun;2(6):644-53. [[Link to article](#)]

van Straaten S, et al. Iron overload in patients with rare hereditary hemolytic anemia: Evidence-based suggestion on whom and how to screen. *American journal of hematology*. 2018 Nov;93(11):E374. [[Link to article](#)]

McDonald CJ, et al. Evaluation of a bone morphogenetic protein 6 variant as a cause of iron loading. *Human genomics*. 2018 Dec;12(1):23 [[Link to article](#)]

Hammond J, et al. Combination Oral Chelation in Adult Patients With Transfusion-dependent Thalassemia and High Iron Burden. *Journal of pediatric hematology/oncology*. 2019 Jan 1;41(1):e47-50. [[Link to abstract](#)]

Jhaveri KS, et al. Prospective Evaluation of an R2* Method for Assessing Liver Iron Concentration (LIC) Against FerriScan: Derivation of the Calibration Curve and Characterization of the Nature and Source of Uncertainty in the Relationship. *Journal of Magnetic Resonance Imaging*. 2019 May;49(5):1467-74. [[Link to abstract](#)]

Alenezi K, et al. Magnetic Resonance Imaging Findings in Neonatal Hemochromatosis. *Journal of pediatric gastroenterology and nutrition*. 2018 Apr 1;66(4):581-7. [[Link to abstract](#)]

Kanbour I, et al. Severe Liver Iron Concentrations (LIC) in 24 Patients with β -Thalassemia Major: Correlations with Serum Ferritin, Liver Enzymes and Endocrine Complications. *Mediterranean journal of hematology and infectious diseases*. 2018;10(1). [[Link to article](#)]

Pirasteh A, et al. Inter-method reproducibility of biexponential R2 MR relaxometry for estimation of liver iron concentration. *Magnetic resonance in medicine*. 2018 Dec;80(6):2691-701. [[Link to article](#)]

Jarisch A, et al. Serum ferritin is not a reliable predictor to determine iron overload in thalassemia major patients post-hematopoietic stem cell transplantation. *European journal of haematology*. 2018 Dec;101(6):791-7. [[Link to abstract](#)]

Kobayashi H, et al. Heterogeneity of intrahepatic iron deposition in transfusion-dependent iron overload patients with hematological malignancies. *Leukemia research*. 2018 Jul 1;70:41-4. [[Link to abstract](#)]

Vichinsky E, et al. Epidemiologic and clinical characteristics of nontransfusion-dependent thalassemia in the United States. *Pediatric Blood & Cancer*. 2018 Apr 10:e27067. [[Link to abstract](#)]

Cancado R, et al. Assessment of liver and cardiac iron overload using MRI in patients with chronic anemias in Latin American countries: results from ASIMILA study. *Hematology*. 2018 Apr 18:1-7. [[Link to abstract](#)]

Vitrano A, et al. Longitudinal changes in LIC and other parameters in patients receiving different chelation regimens: Data from LICNET. *European Journal of Haematology*. 2018 Feb;100(2):124-30. [[Link to abstract](#)]

Amid A, et al. Iron overload in transfusion-dependent survivors of hemoglobin Bart's hydrops fetalis. *Haematologica*. 2018. [[Link to full article](#)]

Ekwattanakit S, et al. Interaction between Hb E and Hb Yala (HBB: c. 129delT); a novel frameshift beta globin gene mutation, resulting in Hemoglobin E/ β^0 thalassemia. *Hematology*. 2018 Feb 7;23(2):117-21. [[Link to abstract](#)]

Yassin MA, et al. Statural growth and prevalence of endocrinopathies in relation to liver iron content (LIC) in adult patients with beta thalassemia major (BTM) and sickle cell disease (SCD). *Acta Bio Medica Atenei Parmensis*. 2018 Feb 16;89(2-S):33-40. [[Link to full article](#)]

Soliman AT, et al. Final adult height and endocrine complications in young adults with β -thalassemia major (TM) who received oral iron chelation (OIC) in comparison with those who did not use OIC. *Acta Bio Medica Atenei Parmensis*. 2018 Feb 16;89(2-S):27-32. [[Link to full article](#)]

Lin H, et al. Quantitative analysis of hepatic iron in patients suspected of coexisting iron overload and steatosis using multi-echo single-voxel magnetic resonance spectroscopy: Comparison with fat-saturated multi-echo gradient echo sequence. *Journal of Magnetic Resonance Imaging*. 2018, Mar 7. [[Link to abstract](#)]

Alenezi, M, et al. Magnetic Resonance Imaging Findings in Neonatal Hemochromatosis. *Journal of Pediatric Gastroenterology and Nutrition*, 2018, 66(4), 581-587. doi:10.1097/MPG.0000000000001880. [[Link to abstract](#)]

Yassin, MA, et al. The Impact of Iron Overload in Patients with Acute Leukemia and Myelodysplastic Syndrome on Hepatic and Endocrine functions. *Acta bio-medica: Atenei Parmensis*, 2018, 89(3-S), 18-22. [[Link to abstract](#)]

Lin, H, et al. Quantitative susceptibility mapping in combination with water-fat separation for simultaneous liver iron and fat fraction quantification. *European Radiology*, 2018, 1-11. [[Link to abstract](#)]

Drasar E, et al. Interim assessment of liver damage in patients with sickle cell disease using new non-invasive techniques. *British Journal of Haematology*. 2017 Feb 1;176(4):643-50. [[Link to full article](#)]

Wang M, et al. Iron overload correlates with serum liver fibrotic markers and liver dysfunction: Potential new methods to predict iron overload-related liver fibrosis in thalassemia patients. *United European Gastroenterology Journal*. 2017 Feb;5(1):94-103. [[Link to full article](#)]

Porter JB, et al. Iron overload across the spectrum of non-transfusion-dependent thalassaemias: role of erythropoiesis, splenectomy and transfusions. *British Journal of Haematology*. 2017 Jan 1;176(2):288-99. [[Link to full article](#)]

Moon J, et al. Efficacy and safety of ledipasvir/sofosbuvir for the treatment of chronic hepatitis C in persons with sickle cell disease. *Clinical Infectious Diseases*. 2017 May 13;65(5):864-6. [[Link to abstract](#)]

FERRISCAN SCIENTIFIC PUBLICATION LIST

- Fareed S, et al. Spinal cord compression secondary to extramedullary hematopoiesis: A rareness in a young adult with thalassemia major. *Acta Bio Medica Atenei Parmensis*. 2017 Aug 23;88(2):237-42. [[Link to full article](#)]
- Porter JB, et al. Limitations of serum ferritin to predict liver iron concentration responses to deferasirox therapy in patients with transfusion-dependent thalassaemia. *European Journal of Haematology*. 2017 Mar 1;98(3):280-8. [[Link to full article](#)]
- Agapidou A, et al. Double heterozygosity for hemoglobin C and beta thalassemia dominant: A rare case of thalassemia intermedia. *Hematology Reports*. 2017 Dec 22;9(4). [[Link to full article](#)]
- Taher AT. Clinical utility of serum ferritin thresholds for guiding iron chelation therapy when magnetic resonance imaging is unavailable in patients with non-transfusion-dependent thalassaemias-response to Ang et al. *British Journal of Haematology*. 2017 Mar 1;176(6):989-90. [[Link to full article](#)]
- Ho PJ, et al. Cardiac iron load and function in transfused patients treated with deferasirox (the MILE study). *European Journal of Haematology*. 2017 Feb 1;98(2):97-105. [[Link to abstract](#)]
- Ou G, et al. Utility of Transient Elastography in Estimating Hepatic Iron Concentration in Comparison to Magnetic Resonance Imaging in Patients Who are Transfusion-Dependent: A Canadian Center Experience. *Hemoglobin*. 2017 Jan 2;41(1):21-5. [[Link to abstract](#)]
- Holman R, et al. Characterization of hepatic and cardiac iron deposition during standard treatment of anaemia in haemodialysis. *Nephrology*. 2017 Feb 1;22(2):114-7. [[Link to abstract](#)]
- Yassin, M, et al. A Young Adult with Unintended Acute Intravenous Iron Intoxication Treated with Oral Chelation: The Use of Liver Ferriscan for Diagnosing and Monitoring Tissue Iron Load. *Mediterranean Journal of Hematology and Infectious Diseases*, 2017; 9(1), e2017008. doi:10.4084/MJHID.2017.008 [[Link to full article](#)]
- Yassin, M, et al. Liver Iron Content (LIC) in Adults with Sickle Cell Disease (SCD): Correlation with Serum Ferritin and Liver Enzymes Concentrations in Trasfusion Dependent (TD-SCD) and Non-Transfusion Dependent (NT-SCD) Patients. *Mediterranean Journal of Hematology and Infectious Diseases*. 2017;9(1):e2017037. doi:10.4084/MJHID.2017.037. [[Link to full article](#)]
- Inati A, et al. One-year results from a prospective randomized trial comparing phlebotomy with deferasirox for the treatment of iron overload in pediatric patients with thalassemia major following curative stem cell transplantation. *Pediatric Blood & Cancer*. 2017 Jan 1;64(1):188-96. [[Link to abstract](#)]
- Taher, AT, et al. Optimising iron chelation therapy with deferasirox for non-transfusion-dependent thalassaemia patients: 1-year results from the THETIS study. *Blood Cells, Molecules, and Diseases*, 2016. 57: p. 23-29. doi: 10.1016/j.bcmd.2015.11.002 [[Link to full article](#)]
- Fasano, RM, et al. Effectiveness of red blood cell exchange, partial manual exchange, and simple transfusion concurrently with iron chelation therapy in reducing iron overload in chronically transfused sickle cell anemia patients. *Transfusion*, 2016: p. n/a-n/a. doi : 10.1111/trf.13558 [[Link to abstract](#)]
- Tsitsikas, DA, et al. Safety, tolerability, and outcomes of regular automated red cell exchange transfusion in the management of sickle cell disease. *Journal of Clinical Apheresis*, 2016. doi: 10.1002/jca.21447 [[Link to abstract](#)]
- Holman, R, et al. Characterisation of hepatic and cardiac iron deposition during standard treatment of anaemia in haemodialysis. *Nephrology*, 2016. doi: 10.1111/nep.12735 [[Link to abstract](#)]
- Schempp, A, et al. Iron Overload in Survivors of Childhood Cancer. *Journal of Pediatric Hematology/Oncology*, 2016. 38(1): p. 27-31. [[Link to abstract](#)]
- Vitrano, A, et al. Real-life experience with liver iron concentration R2 MRI measurement in patients with hemoglobinopathies: baseline data from LICNET. *European Journal of Haematology*, 2016. doi: 10.1111/ejh.12740 [[Link to abstract](#)]
- Calvaruso, G, et al. Exon 12 Ceruloplasmin Gene New Nonsense Mutation Causing Aceruloplasminemia in an Italian Patient. *Open Journal of Internal Medicine*, 2016. 6(01): p. 20. doi: 10.4236/ojim.2016.61005 [[Link to full article](#)]
- Taher, AT, et al. Defining serum ferritin thresholds to predict clinically relevant liver iron concentrations for guiding deferasirox therapy when MRI is unavailable in patients with non-transfusion-dependent thalassaemia. *British Journal of Haematology*, 2015. 168(2): p. 284-290. doi:10.1111/bjh.13119 [[Link to abstract](#)]
- Jones, E, et al. Hcpidin is suppressed by erythropoiesis in hemoglobin E β -thalassemia and β -thalassemia trait. *Blood*, 2015. 125(5): p. 873-880. [[Link to full article](#)]
- Chowdhury, P, et al. Correlation of Serum Ferritin with Hepatic Iron Overload among Nontransfusion Dependent Beta Thalassaemia with Haemoglobin E Disease Patients from Eastern India. *Journal of Molecular Biomarkers & Diagnosis*, 2015. 6(3): p. 1. doi:10.4172/2155-9929.1000231 [[Link to full article](#)]
- Adams, LA, et al. The impact of phlebotomy in nonalcoholic fatty liver disease: A prospective, randomized, controlled trial. *Hepatology*, 2015. 61(5): p. 1555-1564. doi : 10.1002/hep.27662 [[Link to abstract](#)]
- Kohgo, Y, et al. Deferasirox decreases liver iron concentration in iron-overloaded patients with myelodysplastic syndromes, aplastic anemia and other rare anemias. *Acta Haematologica*, 2015. 134(4): p. 233-242. doi : 10.1159/000381893 [[Link to full article](#)]
- Luo, XF, et al. Dual-Energy CT for Patients Suspected of Having Liver Iron Overload: Can Virtual Iron Content Imaging Accurately Quantify Liver Iron Content? *Radiology*, 2015. 277(1): p. 95-103. doi : 10.1148/radiol.2015141856 [[Link to abstract](#)]
- Sharma, SD, et al. Quantitative susceptibility mapping in the abdomen as an imaging biomarker of hepatic iron overload. *Magnetic Resonance in Medicine*, 2015. 74(3): p. 673-683. doi: 10.1002/mrm.25448 [[Link to abstract](#)]
- Wood, JC, et al. Liver MRI is more precise than liver biopsy for assessing total body iron balance: a comparison of MRI relaxometry with simulated liver biopsy results. *Magnetic Resonance Imaging*, 2015. 33(6): p. 761-767. doi: 10.1016/j.mri.2015.02.016 [[Link to abstract](#)]
- Tsouana, E, et al. Deferasirox for iron chelation in multitransfused children with sickle cell disease; long-term experience in the East London clinical haemoglobinopathy network. *European Journal of Haematology*, 2015. 94(4): p. 336-342. Doi: 10.1111/ejh.12435 [[Link to abstract](#)]
- Gutiérrez, L, et al. Tissue Iron Distribution Assessed by MRI in Patients with Iron Loading Anemias. *PLoS ONE*, 2015. 10(9):

FERRISCAN SCIENTIFIC PUBLICATION LIST

- p. e0139220. doi: 10.1371/journal.pone.0139220 [[Link to full article](#)]
- Serai, SD, et al.** Retrospective comparison of gradient recalled echo R2* and spin-echo R2 magnetic resonance analysis methods for estimating liver iron content in children and adolescents. *Pediatric Radiology*, 2015. 45(11): p. 1629-1634. doi: 10.1007/s00247-015-3378-9 [[Link to abstract](#)]
- Taher, AT, et al.** Approaching low liver iron burden in chelated patients with non-transfusion-dependent thalassemia: the safety profile of deferasirox. *European Journal of Haematology*, 2014. 92(6): p. 521-526. doi: 10.1111/ejh.12270 [[Link to abstract](#)]
- Ang, AL, et al.** History of myocardial iron loading is a strong risk factor for diabetes mellitus and hypogonadism in adults with β thalassemia major. *European Journal of Haematology*, 2014. 92(3): p. 229-236. doi:10.1111/ejh.12224 [[Link to abstract](#)]
- Tsitsikas, DA, et al.** Comparison of serial serum ferritin measurements and liver iron concentration assessed by MRI in adult transfused patients with sickle cell disease. *European Journal of Haematology*, 2014. 92(2): p. 164-167. doi: 10.1111/ejh.12230 [[Link to abstract](#)]
- Tzoulis, P, et al.** Joint diabetes thalassaemia clinic: An effective new model of care. *Hemoglobin*, 2014. 38(2): p. 104-110. doi: 10.3109/03630269.2013.862541 [[Link to abstract](#)]
- El Beshlawy, A, et al.** Low prevalence of cardiac siderosis in heavily iron loaded Egyptian thalassemia major patients. *Annals of Hematology*, 2014. 93(3): p. 375-379. doi: 10.1007/s00277-013-1876-0 [[Link to abstract](#)]
- Wood, JC, et al.** R2 and R2* are equally effective in evaluating chronic response to iron chelation. *American Journal of Hematology*, 2014. 89(5): p. 505-508. doi: 10.1002/ajh.23673 [[Link to abstract](#)]
- Cheong, J-W, et al.** Deferasirox improves hematologic and hepatic function with effective reduction of serum ferritin and liver iron concentration in transfusional iron overload patients with myelodysplastic syndrome or aplastic anemia. *Transfusion*, 2014. 54(6): p. 1542-1551. doi: 10.1111/trf.12507 [[Link to abstract](#)]
- Garbowski, MW, et al.** Biopsy-based calibration of T2* magnetic resonance for estimation of liver iron concentration and comparison with R2 Ferriscan. *Journal of Cardiovascular Magnetic Resonance*, 2014. 16: p. 11. doi: 10.1186/1532-429x-16-40 [[Link to full article](#)]
- Chan, WC, et al.** R2* as a surrogate measure of ferriscan iron quantification in thalassemia. *Journal of Magnetic Resonance Imaging*, 2014. 39(4): p. 1007-1011. doi: 10.1002/jmri.24216 [[Link to abstract](#)]
- Nichols-Vinueza, DX, et al.** MRI guided iron assessment and oral chelator use improve iron status in thalassemia major patients. *American Journal of Hematology*, 2014. 89(7): p. 684-688. doi: 10.1002/ajh.23715 [[Link to abstract](#)]
- Viprakasit, V, et al.** Geographical variations in current clinical practice on transfusions and iron chelation therapy across various transfusion-dependent anaemias. *Blood Transfusion*, 2013. 11(1): p. 108-122. [[Link to full article](#)]
- Hernando, D, et al.** Magnetic susceptibility as a B0 field strength independent MRI biomarker of liver iron overload. *Magnetic Resonance in Medicine*, 2013. 70(3): p. 648-656. doi: 10.1002/mrm.24848 [[Link to abstract](#)]
- Trottier, BJ, et al.** Association of iron overload with allogeneic hematopoietic cell transplantation outcomes: a prospective cohort study using R2-MRI-measured liver iron content. *Blood*, 2013. 122(9): p. 1678-1684. [[Link to full article](#)]
- Porter JB et al.** Efficacy and safety of deferasirox at low and high iron burdens: results from the EPIC magnetic resonance imaging sub study. *Ann Hematol.* 2013 Jan;92(2):211-9 [[Link to abstract](#)]
- Nolte F et al.** Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload. *Ann Hematol.* 2013 Jan;92(2):191-8 [[Link to abstract](#)]
- Wermke M et al.** MRI-based liver iron content predicts for non-relapse mortality in MDS and AML patients undergoing allogeneic stem cell transplantation. *Clinical Cancer Research.* 2012; Sept 18. DOI:10.1158/1078-0432.CCR-12-1683 [Epub ahead of print]. [[Link to abstract](#)]
- Kwiatkowski J et al.** Chelation use and iron burden in North America and British Thalassemia patients: a report from the Thalassemia Longitudinal Cohort. *Blood.* 2012; 119:2746-2753. [[Link to abstract](#)]
- St Pierre TG et al.** Spin-density-projection-assisted R2 magnetic resonance imaging of the liver in the management of body iron stores in patients receiving multiple red blood cell transfusions: an audit and retrospective study in South Australia. *Internal Medicine Journal.* 2012; 42(9):990-6. doi: 10.1111/j.1445-5994.2012.02845.x [[Link to abstract](#)]
- Neufeld EJ et al.** A phase 2 study of the safety, tolerability and pharmacodynamics of FBS0701, a novel oral iron chelator, in tranfusional iron overload. *Blood.* 2012; 119:3263-8. [[Link to abstract](#)]
- Cheng H-L et al.** Liver iron overload assessment by T2* magnetic imaging in pediatric patients: An accuracy and reproducibility study. *Am J Hematol.* 2012; Jan 28. DOI: 10.1002/ajh.23114 [[Link to abstract](#)]
- Vasavda A et al.** Renal iron load in sickle cell disease is influenced by severity of hemolysis. *Brit J Haematol.* 2012; 157(5):599-605. Doi: 10.1111/j.1365-2141.2012.09093.x [[Link to abstract](#)]
- Drasar E et al.** Serum ferritin and total units transfused for assessing iron overload in adults with sickle cell disease. *Brit J Haematol.* 2012; 157:637-50. [[Link to full article](#)]
- Taher A et al.** Importance of optimal dosing ≥ 30 mg/kg/d during deferasirox treatment: 2.7-yr follow-up from the ESCALATOR study in patients with β -thalassaemia. *Eur J Haem.* 2011; 87:355-65. [[Link to abstract](#)]
- Pavitt H et al.** The effect of reducing repetition time TR on the measurement of liver R2 for the purpose of measuring liver iron concentration. *Mag Reson Med.* 2011; 65(5):1346-51. [[Link to abstract](#)]
- Pennell DJ et al.** Continued improvement in myocardial T2* over two years of deferasirox therapy in beta-thalassemia major patients with cardiac iron overload. *Haematologica.* 2011; 96(1):48-54. [[Link to abstract](#)]
- Ferrari P et al.** Serum iron markers are inadequate for guiding iron repletion in chronic kidney disease. *Clin J Am Soc Nephrol.* 2011; 6(1):77-83. [[Link to abstract](#)]
- Musallam KM et al.** Elevated liver iron concentration is a marker of increased morbidity in patients with beta-thalassaemia intermedia. *Haematologica.* 2011. 96(11):1605-12. [[Link to abstract](#)]
- Inati A et al.** Non-transferrin bound iron in transfused patients with sickle cell disease. *Int J Lab Hematol.* 2011; 33(2):133-7. [[Link to abstract](#)]

FERRISCAN SCIENTIFIC PUBLICATION LIST

- Taher A et al. Achieving treatment goals of reducing or maintaining body iron burden with deferasirox in patients with β -thalassaemia: results from the ESCALATOR study. *European J Haematol.* 2011; 87(4):349-54. [\[Link to abstract\]](#)
- House M et al. Relationship between brain R(2) and liver and serum iron concentrations in elderly men. *Mag Reson Med.* 2010; 63:275-81. [\[Link to abstract\]](#)
- Patton N et al. Observational study of iron overload as assessed by magnetic resonance imaging (MRI) in an adult population of transfusion dependent patients with beta thalassaemia: Significant association between low cardiac T2* < 10 ms and the occurrence of cardiac events. *Intern Med J* 2010; 40: 419-26. [\[Link to abstract\]](#)
- Greenberg P et al. Prospective assessment of effects of iron-overload parameters of deferasirox therapy in patients with myelodysplastic syndromes. *Leuk Res.* 2010; 34(12):1560-5. [\[Link to abstract\]](#)
- Majhail NS et al. A prospective study of iron-overload management in allogeneic hematopoietic-cell transplant survivors. *Biol Blood Marrow Transplant.* 2010; 16(5):832-7. [\[Link to abstract\]](#)
- Pathare A et al. Deferasirox (Exjade®) significantly improves cardiac T2* in heavily iron-overloaded patients with beta-thalassaemia major. *Ann Hematol* 2010; 89(4):405-9. [\[Link to abstract\]](#)
- Pennell DJ et al. Efficacy of deferasirox in reducing and preventing cardiac iron overload in β -thalassaemia. *Blood* 2010; 115(12):2364-71. [\[Link to abstract\]](#)
- Taher A et al. Magnetic resonance evaluation of hepatic and myocardial iron deposition in transfusion-independent thalassaemia intermedia compared to regularly transfused thalassaemia major patients. *Am J Hematol.* 2010; 85(4): 288-90. [\[Link to abstract\]](#)
- Taher A et al. Levels of non-transferrin-bound iron as an index of iron overload in patients with thalassaemia intermedia. *Br J Haematol* 2009;146(5):569-572. [\[Link to abstract\]](#)
- Inati A et al. Absence of cardiac siderosis by MRI T2* despite transfusion burden, hepatic and serum iron overload in Lebanese patients with sickle cell disease. *Eur J Haematol* 2009; 83(6):565-71. [\[Link to abstract\]](#)
- Majhail NS et al. Iron-overload after autologous hematopoietic cell transplantation. *Leuk Res* 2009;33(4):578-579. [\[Link to abstract\]](#)
- Olynyk J et al. Predicting iron overload in hyperferritinemia. *Clinical Gastroenterology and Hepatology.* 2009;7(3):359-362. [\[Link to abstract\]](#)
- Angulo IL et al. Determination of iron-overload in thalassaemia by hepatic MRI and ferritin. *Revista Brasileira De Hematologia E Hemoterapia* 2008;30(6):449-452. [\[Link to full text\]](#)
- Isma'eel H et al. Relation between iron-overload indices, cardiac echo-Doppler, and biochemical markers in thalassaemia intermedia. *Am J Cardiol* 2008;102(3):363-367. [\[Link to abstract\]](#)
- Majhail NS et al. High prevalence of iron overload in adult allogeneic hematopoietic cell transplant survivors. *Biol Blood Marrow Transplant* 2008;14(7):790-794. [\[Link to abstract\]](#)
- Melis MA et al. A mutation in the TMPRSS6 gene, encoding a transmembrane serine protease that suppresses hepcidin production, in familial iron deficiency anemia refractory to oral iron. *Haematologica* 2008;93(10):1473-1479. [\[Link to abstract\]](#)
- Origa R et al. No evidence of cardiac iron in 20 never- or minimally-transfused patients with thalassaemia intermedia. *Haematologica* 2008;93(7):1095-1096. [\[Link to full article\]](#)
- Taher A et al. Correlation of liver iron concentration determined by R2 magnetic resonance imaging with serum ferritin in patients with thalassaemia intermedia. *Haematologica* 2008;93(10):1584-1586. [\[Link to full text article\]](#)
- Carneiro AA et al. Liver iron concentration evaluated by two magnetic methods: magnetic resonance imaging and magnetic susceptibility. *Magn Reson Med* 2005;54(1):122-128. [\[Link to abstract\]](#)
- Olynyk JK et al. Duration of hepatic iron exposure increases the risk of significant fibrosis in hereditary hemochromatosis: a new role for magnetic resonance imaging. *Am J Gastroenterol* 2005;100(4):837-841. [\[Link to abstract\]](#)
- St Pierre TG et al. Measurement and mapping of liver iron concentrations using magnetic resonance imaging. *Ann N Y Acad Sci.* 2005;1054:379-85. [\[Link to abstract\]](#)
- St Pierre TG et al. Single spin-echo proton transverse relaxometry of iron-loaded liver. *NMR Biomed* 2004;17(7):446-458. [\[Link to abstract\]](#)
- Clark PR et al. Bi-exponential proton transverse relaxation rate (R2) image analysis using RF field intensity-weighted spin density projection: potential for R2 measurement of iron-loaded liver. *Magn Reson Imaging* 2003;21(5):519-530. [\[Link to abstract\]](#)
- Clark PR et al. Proton transverse relaxation rate (R2) images of liver tissue; mapping local tissue iron concentrations with MRI. *Magn Reson Med.* 2003 Mar;49(3):572-5. [\[Link to abstract\]](#)

EDITORIALS

- Angelucci, E. Another Step Forward in Iron Chelation Therapy. *Acta Haematologica*, 2015. 134(4): p. 231-232. doi: 10.1159/000431215 [\[Link to abstract\]](#)
- Savani, BN. Ferritin and FerriScan in HCT recipients. *Blood*, 2013. 122(9): p. 1539-1541. doi: 10.1182/blood-2013-07-511014 [\[Link to full article\]](#)

REVIEW ARTICLES

- Pandey P, et al. Assessing the Non-tumorous Liver: Implications for Patient Management and Surgical Therapy. *Journal of Gastrointestinal Surgery.* 2018 Feb 1;22(2):344-60. [\[Link to abstract\]](#)
- Yan F, et al. Iron deposition quantification: Applications in the brain and liver. *Journal of Magnetic Resonance Imaging.* 2018 Aug;48(2):301-17. [\[Link to abstract\]](#)
- Shah F, et al. Management of Thalassaemias. The Obstetric Hematology Manual. 2018 Feb 8;1:66. [\[Link to chapter\]](#)
- Ginzburg YZ, Vinchi F. Iron Overload. In *Transfusion Medicine and Hemostasis* 2019 Jan 1 (pp. 433-436). Elsevier. [\[Link to chapter\]](#)
- Fernandes JL. MRI for Iron Overload in Thalassaemia. *Hematology/Oncology Clinics.* 2018 Apr 1;32(2):277-95. [\[Link to abstract\]](#)

FERRISCAN SCIENTIFIC PUBLICATION LIST

- Inamoto Y, Lee SJ. Late effects of blood and marrow transplantation. *Haematologica*. 2017 Apr 1;102(4):614-25. [[Link to abstract](#)]
- Echeverría JA, et al. Diagnosis and quantification of the iron overload through magnetic resonance. *Radiologia* (English Edition). 2017 Dec 31;59(6):487-95. [[Link to abstract](#)]
- Courtier J, et al. Advanced imaging techniques in pediatric body MRI. *Pediatric Radiology*. 2017 May 1;47(5):522-33. [[Link to abstract](#)]
- Lee JS, et al. Cancer therapy: shooting for the moon. *Clinical Pharmacology & Therapeutics*. 2017 May 1;101(5):552-8. [[Link to full article](#)]
- Scheerens H, et al. Current status of companion and complementary diagnostics: strategic considerations for development and launch. *Clinical and Translational Science*. 2017 Mar 1;10(2):84-92. [[Link to full article](#)]
- Jørgensen JT, Hersom M. Clinical and Regulatory Aspects of Companion Diagnostic Development in Oncology. *Clinical Pharmacology & Therapeutics*. 2017 Dec 2. [[Link to abstract](#)]
- Ramanathan G, et al. Diagnosing and preventing iron overload. *Hemodialysis International*. 2017 Jun 1;21(S1). [[Link to full article](#)]
- Ruefer A, et al. Role of liver magnetic resonance imaging in hyperferritinaemia and the diagnosis of iron overload. *Swiss Medical Weekly*. 2017 Nov 9;147:w14550-. [[Link to full article](#)]
- Paisant A, et al. MRI for the measurement of liver iron content, and for the diagnosis and follow-up of iron overload disorders. *La Presse Médicale*. 2017 Dec 1;46(12):e279-87. [[Link to abstract](#)]
- Kawel-Boehm N, Bluemke DA. Cardiovascular imaging environment: will the future be cloud-based?. *Expert Review of Medical Devices*. 2017 Jul 3;14(7):521-8. [[Link to abstract](#)]
- Murray, C, et al. Management of iron overload in the Canadian hematology/oncology population: Implications for nursing practice. *Canadian Oncology Nursing Journal/Revue canadienne de soins infirmiers en oncologie*, 2016. 26(1): p. 19-28. [[Link to full article](#)]
- Sarigianni, M, et al. Accuracy of Magnetic Resonance Imaging in Diagnosis of Liver Iron Overload: A Systematic Review and Meta-analysis. *Clinical Gastroenterology and Hepatology*, 2015. 13(1): p. 55-63.e5. doi: 10.1016/j.cgh.2014.05.027 [[Link to abstract](#)]
- Quinn, CT and TG St Pierre. MRI Measurements of Iron Load in Transfusion-Dependent Patients: Implementation, Challenges, and Pitfalls. *Pediatric Blood & Cancer*, 2015. doi: 10.1002/pbc.25882 [[Link to abstract](#)]
- Wood, JC. Estimating tissue iron burden: current status and future prospects. *British Journal of Haematology*, 2015 doi: 10.1111/bjh.13374 [[Link to abstract](#)]
- Hansen, L and SS Slater. Long-Term Follow-Up and Survivorship, in Blood and Marrow Transplant Handbook: Comprehensive Guide for Patient Care, TR Maziarz and SS Slater, Editors. 2015, Springer International Publishing: Cham. p. 407-426. doi: 10.1007/978-3-319-13832-9_34 [[Link to abstract](#)]
- Hernando, D, et al. Quantification of liver iron with MRI: State of the art and remaining challenges. *Journal of Magnetic Resonance Imaging*, 2014 doi: 10.1002/jmri.24584 [[Link to abstract](#)]
- Sheth, S. Iron chelation: an update. *Current Opinion in Hematology*, 2014. 21(3): p. 179-185. [[Link to abstract](#)]
- Wood, JC. Use of Magnetic Resonance Imaging to Monitor Iron Overload. *Hematology-Oncology Clinics of North America*, 2014. 28(4): p. 747. [[Link to first page preview](#)]
- Hope, TA, et al. MR imaging of diffuse liver disease: from technique to diagnosis. *Radiologic Clinics of North America*, 2014. 52(4): p. 709-724. [[Link to first page preview](#)]
- Alexiou, E. Methodologies and tools used today for measuring iron load. *Thalassemia Reports*, 2014. 4(3). [[Link to full article](#)]
- Holman, R. Clinical edge: Diagnosing haemochromatosis. *Medicus*, 2013. 53(6): p. 46.
- Olivieri, NF and GM Brittenham. Management of the Thalassemias. *Cold Spring Harbor Perspectives in Medicine*, 2013. 3(6). [[Link to full article](#)]
- Castiella, A, et al. Is MRI becoming the new gold standard for diagnosing iron overload in hemochromatosis and other liver iron disorders? *Imaging in Medicine*, 2013. 5(6): p. 515-524.
- Towbin, AJ, et al. Magnetic Resonance Imaging of the Pediatric Liver: Imaging of Steatosis, Iron Deposition, and Fibrosis. *Magnetic Resonance Imaging Clinics of North America*, 2013. 21(4): p. 669-680. [[Link to first page preview](#)]
- Shibata, M and S Taniguchi. Iron Supplementation Therapy in End-Stage Renal Disease Patients on Maintenance Hemodialysis. *Cardiovascular & Haematological Disorders - Drug Targets (Formerly Current Drug Targets - Cardiovascular & Hematological Disorders)*, 2013. 13(3): p. 237-242. [[Link to abstract](#)]
- Ware HM, Kwiatkowski JL: Optimal use of iron chelators in pediatric patients. *Clinical Advances in Hematology & Oncology* 2013, 11:433-441. [[Link to full article](#)]
- Juchems MS et al. Liver iron content determined by MRI: Spin-Echo vs Gradient-Echo. *Rofo*. 2012; 184: 427-431. [[Link to abstract](#)]
- Kruger PC et al. Assessing iron overload: Are we there yet? *Clin Cancer Res*. 2012. Nov 19. Epub ahead of print. [[Link to abstract](#)]
- Fleming RE and Ponka P. Iron overload in human disease. *N Engl J Med*. 2012; 366:348-59 [[Link to abstract](#)]
- Alustiza Echeverria JM et al. Quantification of iron concentration in the liver by MRI. *Insights Imaging*. 2012; 3:173-80. [[Link to abstract](#)]
- Bird RJ et al. When should iron chelation therapy be considered in patients with myelodysplasia and other bone marrow failure syndromes with iron overload? *Internal Medicine Journal*. 2012; 42:450-5. [[Link to abstract](#)]
- Muñoz M. et al. Disorders of iron metabolism. Part II: iron deficiency and iron overload. *J Clin Pathol*. 2011;64:287-296 [[Link to paper](#)]
- Kwiatkowski J. Management of transfusional iron overload - differential properties and efficacy of iron chelating agents. *J Blood Med*. 2011; 2(135-149). [[Link to abstract](#)]
- Taher AT et al. Optimal management of α -thalassaemia intermedia. *British Journal of Haematology*. 2011; 152: 512-23. [[Link to abstract](#)]
- Cao A et al. Recent advances in α -thalassemias. *Pediatric Reports*. 2011; 3:e17. [[Link to abstract](#)]
- Tziomalos K and Perifanis V. Liver iron content determination by magnetic resonance imaging. *World J Gastro*. 2010. 16(13): 1587-97. [[Link to abstract](#)]
- Araujo A et al. Management of transfusional iron overload in Latin America: current outlook and expert panel

FERRISCAN SCIENTIFIC PUBLICATION LIST

- recommendations. *Hematology* 2009;14(1):22-32. [[Link to abstract](#)]
- Cappellini M et al. Insight onto the pathophysiology and clinical complications of thalassemia intermedia. *Hemoglobin* 2009; 33(S1): S145-S159. doi: 10.3109/03630260903351528 [[Link to abstract](#)]
- El Rassi F et al. Beta-thalassemia intermedia: an overview. *Pediatr Ann* 2008;37(5):322-328. [[Link to PubMed listing](#)]
- Majhail NS et al. Iron overload in hematopoietic cell transplantation. *Bone Marrow Transplant* 2008;41(12):997-1003. [[Link to abstract](#)]
- Wood J et al. Magnetic Resonance Imaging assessment of excess iron in thalassemia, sickle cell disease and other iron overload diseases. *Hemoglobin* 2008;32(1-2):85-96. [[Link to full article](#)]
- Alustiza JM et al. Iron overload in the liver diagnostic and quantification. *Eur J Radiol* 2007;61(3):499-506. [[Link to abstract](#)]
- Pavenski K et al. The real cost of iron chelation therapy. *Transfusion* 2007;47(10):1751-1752. [[Link to Pubmed listing](#)]
- Wood J et al. Magnetic resonance imaging measurement of iron overload. *Curr Opin Hematology* 2007;14(3):183-190. [[Link to full article](#)]
- Neufeld E. Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major; new data, new questions. *Blood*. 2006; 107:3436-3441. doi: 10.1182/blood-2006-02-002394 [[Link to full article](#)]
- Zoller H et al. Hemochromatosis: genetic testing and clinical practice. *Clin Gastroenterol Hepatol* 2005;3(10):945-958. [[Link to abstract](#)]
- Rossi E et al. Clinical Penetrance of C282Y Homozygous HFE Haemochromatosis. *Clin Biochem Rev* 2004;25(3):183-190. [[Link to abstract](#)]
- St Pierre, T, et al. Measurement of Liver Iron Concentration in a Population of Non-Transfusion Dependent Thalassemia Patients Using a Trained Artificial Neural Network to Analyse Magnetic Resonance Images. *Blood*, 2017 130(Suppl 1), 2212. [[Link to abstract](#)]
- Oliva, EN, et al. Surrogate Thresholds for Iron Chelation in Patients with Hematological Malignancies. *Blood*, 2017, 130(Suppl 1), 3499. [[Link to abstract](#)]
- Chowdhury, PK, et al. Profile of Iron Overload in Nontransfusion Dependent Hb E Beta Thalassaemia Patients- Is It Different? *Blood*, 2015. 126(23): p. 4557. [[Link to abstract](#)]
- Ware, RE, et al. TCD with Transfusions Changing to Hydroxyurea (TWITCH): Hydroxyurea Therapy As an Alternative to Transfusions for Primary Stroke Prevention in Children with Sickle Cell Anemia. *Blood*, 2015. 126(23): p. 3-3. [[Link to abstract](#)]
- Yassin, MA, et al. Increased Liver Iron Concentration (LIC) in Adults with Non-Transfusion Dependent Sickle Cell Disease (NTD-SCD): Correlation with Serum Ferritin Concentrations. *Blood*, 2015. 126(23): p. 4594. [[Link to abstract](#)]
- Vitrano, A, et al. Different Thresholds of Serum Ferritin Levels for Prediction of Liver Iron Concentration in Hemoglobinopathies. *Blood*, 2015. 126(23): p. 2146. [[Link to abstract](#)]
- Calvaruso, G, et al. Central Role of LIC-R2 (Ferriscan®) Determination in Patients with Hemoglobinopathies: LICNET Experience. *Blood*, 2014. 124(21): p. 4034. [[Link to abstract](#)]
- Brown, RC, et al. A Quick, Robust Protocol for Liver Iron Quantitation on 3.0 Tesla MRI Scanners. *Blood*, 2014. 124(21): p. 4069. [[Link to abstract](#)]
- Ezzat, H. Utility of Transient Elastography (Fibroscan) in Estimating Hepatic Iron Concentration in Comparison to MRI in Patients with Transfusion Dependent Hemoglobinopathies. *Blood*, 2014. 124(21): p. 4888. [[Link to abstract](#)]
- Wood, JC, et al. Liver Iron Concentration By MRI In Chronically Transfused Children With Sickle Cell Anemia In The Twitch Trial. *Blood*, 2013. 122(21): p. 780. [[Link to abstract](#)]
- Wood, JC, et al. R2 and R2* Are Equally Effective In Evaluating Chronic Response To Iron Chelation. *Blood*, 2013. 122(21): p. 3437. [[Link to abstract](#)]
- St Pierre, TG, et al. Assessment Of Non-Transfusional Iron Accumulation In Asian Patients With Hemoglobin E β Thalassemia. *Blood*, 2013. 122(21): p. 2262. [[Link to abstract](#)]
- Nichols-Vinueza, DX, et al. MRI-Guided Iron Assessment and Oral Chelator Use Improve Iron Status In Thalassemia Major Patients: a Six-Year Single Center Retrospective Cohort Study. *Blood*, 2013. 122(21): p. 563. [[Link to abstract](#)]
- Taher A et al. Deferasirox significantly reduces liver iron concentration in non-transfusion-dependent Thalassemia patients with iron overload: results from the 1-year randomised, double-blind, placebo-controlled phase II THALASSA study. ASH Annual Meeting. 2011; Abstract 902.
- Neufeld E et al. Safety, tolerability and dose response of FBS0701, a novel iron chelator for treatment of transfusional iron overload: results of a 24-week multi-centre, international Phase 2 study. ASH Annual Meeting. 2011; Abstract 690.
- Min Y-H et al. Hematologic improvement with iron chelation using therapy Deferasirox in patients with aplastic anemia: A subgroup analysis of KAMS0112 prospective study. ASH Annual Meeting. 2011; Abstract 3424.

CONFERENCE PROCEEDINGS

- Soliman A, Yassin M. Glycemic Abnormalities and Normal Thyroid Function in Adolescent Survivors of Childhood Acute Lymphocytic Leukemia Who Required Repeated Packed Red Cell Transfusion During Treatment. In 57th Annual ESPE 2018 Aug 28 (Vol. 89). *European Society for Paediatric Endocrinology*. [[Link to abstract](#)]
- DePriest BP, Huang M. Assessment of Iron Overload in the Pediatric Allogeneic HSCT Recipient. *Blood*. 2018 132(S1):5735. [[Link to abstract](#)]
- Yassin MA, et al. Jadenu Substituting Exjade in Beta Thalassemia Major (BTM) Patients with Iron Overload: Effect on Serum Ferritin Concentration, Liver Iron Content and Biochemical Profiles. *Blood*. 2018 132(S1):4905. [[Link to abstract](#)]
- Tang AY, et al. Cardiac Iron Overload in Sickle Cell Disease: When to Screen and How to Intervene. *Blood*. 2018 132(S1):528. [[Link to abstract](#)]
- St Pierre, TG, et al. The effect of liver steatosis on non-invasive measurement of liver iron concentration by spin-density projection assisted R2-MRI (FerriScan®). *Journal of Hepatology*. 2017 Jan 1;66(1):S675-6. [[Link to abstract](#)]
- Schloemer, N, et al. Phlebotomy for Pediatric and Young Adult Oncology Patients Treats Transfusional Iron Overload. *Blood*, 2017, 130 (Suppl 1), 941. [[Link to abstract](#)]

FERRISCAN SCIENTIFIC PUBLICATION LIST

- Vasavda N et al.** Renal iron load in sickle cell disease correlates with hemolysis and transfusion history, but not with hepatic iron. *ASH Annual Meeting*. 2011; Abstract 2129.
- Inati A et al.** Relationship between total iron removed by phlebotomy and iron removed from the liver in pediatric thalassemia major patients following curative stem cell transplant. *ASH Annual Meeting*. 2011; Abstract 5300.
- Kogho Y et al.** Deferasirox decreases liver iron concentration (LIC) in transfusional iron overloaded patients with myelodysplastic syndromes (MDS), aplastic anemia (AA) and other rare anemias: Results from 1-year multi-centre, open-label phase II study. *ASH Annual Meeting*. 2011; Abstract 4838.
- Gatterman N et al.** Transfused myelodysplastic syndromes (MDS) patients have severe iron overload and relevant improvements in iron burden and liver function with deferasirox treatment: results from a pooled analysis. *ASH Annual Meeting*. 2011; Abstract 5019.
- Blair AB et al.** Transfusional iron overload in acute lymphoblastic leukemia. In: Arceci RJ, editor. *American Society of Pediatric Hematology/ Oncology - 22nd Annual Meeting San Diego, California April 22-25, 2009*. Volume 52: *Pediatric Blood & Cancer*; 2009. p 707. Poster 124.
- Cheong J-W et al.** Efficacy of ICT with Deferasirox in transfusional iron overload patients with MDS or AA. *ASH Annual Meeting Abstract*. 2009; Abstract 3810. [\[Link to abstract\]](#)
- Pennell D et al.** Efficacy and safety of Deferasirox (Exjade®) in β -thalassemia patients with myocardial siderosis - 2 year results from the EPIC cardiac sub-study. *ASH Annual Meeting Abstract*. 2009; Abstract 4062. [\[Link to abstract\]](#)
- Taher A et al.** Deferasirox (Exjade®) ≥ 30 mg/kg/day is effective in reducing iron burden in thalassemia major patients previously chelated with monotherapy or combination therapy. *ASH Annual Meeting Abstract*. 2009; Abstract 4058. [\[Link to abstract\]](#)
- Min Y et al.** A multi-centre, open label study evaluating the efficacy of iron chelation therapy with deferasirox in transfusional iron overload patients with myelodysplastic syndromes or aplastic anemia using quantitative R2 MRI. *Leukaemia Research* 33: Supplement 1. 2009:S119-S120.
- Capellini M et al.** Efficacy and safety of once-daily iron chelator Deferasirox (Exjade®) in a large group of regularly transfused patients with β -thalassemia major. *Blood (ASH Annual Meeting Abstracts)* 2008; 112: Abstract 3878. [\[Link to abstract\]](#)
- Capellini M et al.** Efficacy and safety of Deferasirox (Exjade®) in patients with transfusion-dependent anemias: 1 year results from the large, prospective, multi-centre, EPIC study. *Blood (ASH Annual Meeting Abstracts)* 2008; 112: Abstract 3875. [\[Link to abstract\]](#)
- Porter J et al.** Efficacy and safety of 1 year's treatment with Deferasirox (Exjade®): Assessment of regularly transfused patients with Diamond-Blackfan anemia enrolled in the EPIC study. *Blood (ASH Annual Meeting Abstracts)* 2008; 112: Abstract 1046. [\[Link to abstract\]](#)
- Taher A et al.** Deferasirox (Exjade®) treatment in pediatric β -thalassemia patients with high iron burden: 2.8 years results from ESCALATOR trial. *Blood (ASH Annual Meeting Abstracts)* 2008; 112: Abstract 3879. [\[Link to abstract\]](#)
- Taher A et al.** Efficacy and safety of once-daily oral deferasirox (Exjade®) during a median of 2.7 years of treatment in heavily iron-overloaded patients with β -thalassemia. *Blood (ASH Annual Meeting Abstracts)* 2008; 112: Abstract 5409. [\[Link to abstract\]](#)
- Porter J et al.** Deferasirox efficacy and safety for the treatment of transfusion-dependent iron overload in patients with a range of rare anemias. *Blood (ASH Annual Meeting Abstracts)* 2008; 112: Abstract 1419. [\[Link to abstract\]](#)
- Porter J et al.** Effect of Deferasirox (Exjade®) on labile plasma iron levels in heavily iron-overloaded patients with transfusion-dependent anemias enrolled in the large-scale, prospective, 1-year EPIC trial. *Blood (ASH Annual Meeting Abstracts)* 2008; 112: Abstract 3881. [\[Link to abstract\]](#)
- Pennell D et al.** Efficacy and safety of Deferasirox (Exjade®) in reducing cardiac iron in patients with β -thalassemia major: Results from the cardiac substudy of the EPIC trial. *Blood (ASH Annual Meeting Abstracts)* 2008; 112: Abstract 3873. [\[Link to abstract\]](#)
- Pennell D et al.** Efficacy and safety of Deferasirox (Exjade®) in preventing cardiac iron in patients with normal baseline cardiac iron: Results from the cardiac substudy of the EPIC trial. *Blood (ASH Annual Meeting Abstracts)* 2008; 112: Abstract 3874. [\[Link to abstract\]](#)
- Gatterman N et al.** Efficacy and safety of Deferasirox (Exjade®) during 1 year of treatment in transfusion-dependent patients with myelodysplastic syndromes: Results from EPIC trial. *Blood (ASH Annual Meeting Abstracts)* 2008; 112: Abstract 633. [\[Link to abstract\]](#)
- Porter J et al.** Efficacy and safety of 1 year's treatment with Deferasirox (Exjade®): Assessment of regularly transfused patients with Diamond-Blackfan anemia enrolled in the EPIC study. *Blood (ASH Annual Meeting Abstracts)* 2008; 112: Abstract 1048. [\[Link to abstract\]](#)
- Min Y-H et al.** A Multi-Center, Open Label Study Evaluating the Efficacy of Iron Chelation Therapy with Deferasirox in Transfusional Iron Overload Patients with Myelodysplastic Syndromes or Aplastic Anemia Using Quantitative R2 MRI. *Blood (ASH Annual Meeting Abstracts)* 2008; 112: Abstract 3649. [\[Link to abstract\]](#)
- Lee J et al.** Iron chelation in regularly transfused patients with aplastic anemia: Efficacy and safety results from the large Deferasirox EPIC trial. *Blood (ASH Annual Meeting Abstracts)* 2008; 112: Abstract 3649. [\[Link to abstract\]](#)
- Greenberg P et al.** Change in liver iron concentration (LIC), serum ferritin (SF) and labile plasma iron (LPI) over 1 year of Deferasirox (DFX/Exjade®) therapy in a cohort of myelodysplastic patients. *Blood (ASH Annual Meeting Abstracts)* 2008; 112: Abstract 5083. [\[Link to abstract\]](#)
- Piga A et al.** Comparison of LIC obtained from biopsy, BLS and R2-MRI in iron overloaded patients with beta-thalassemia, treated with Deferasirox (Exjade®), ICL670). *Blood (ASH Annual Meeting Abstracts)* 2005; 106: Abstract 2689. [\[Link to abstract\]](#)
- St Pierre T et al.** A new model for predicting venesection therapy requirements in hereditary hemochromatosis using non-invasive liver iron concentration measurement. *Blood (ASH Annual Meeting Abstracts)* 2005; 1106: Abstract 3596.